Market Cap 24.46B
Revenue (ttm) 3.25B
Net Income (ttm) -1.29B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -39.59%
Debt to Equity Ratio 0.02
Volume 1,176,600
Avg Vol 1,243,146
Day's Range N/A - N/A
Shares Out 252.88M
Stochastic %K 9%
Beta 1.29
Analysts Strong Sell
Price Target $122.00

Company Profile

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin a...

Industry: Biotechnology
Sector: Healthcare
Phone: 49 6131 9084
Fax: 49 6131 9084
Address:
An der Goldgrube 12, Mainz, Germany
AIIAAIIA_88
AIIAAIIA_88 Sep. 13 at 5:02 PM
$BNTX MRNA's success against melanoma is like a child's play when compared to BNTX's success against small call lung cancer. The mRNA method has been used successfully against skin cancer for some time. The medical field knows about it. But SCLC is very tough. BNTX's P 1/2b data are not just great. It is wildly beyond what has been expected for SCLC. It is groundbreaking. Anyone who wants to downplay is either intentionally lying or extremely ignorant. JMO
0 · Reply
fredbull
fredbull Sep. 13 at 4:22 PM
$BNTX triple from here
0 · Reply
wintogether
wintogether Sep. 13 at 2:57 PM
$BNTX obviously happy for my small holdings here, but really hopeful for the patients and the field. These guys are proving to be the best in class.
0 · Reply
cubie
cubie Sep. 13 at 1:35 PM
$BNTX $MRNA @YOLODiamondHand congrats giddy bulls
1 · Reply
eightytwentie
eightytwentie Sep. 13 at 3:34 AM
$BNTX PD-L1 x VEGF-A bispecific antibody plus B7H3 antibody-drug conjugate show 70.4% ORR
0 · Reply
eightytwentie
eightytwentie Sep. 13 at 3:32 AM
$BNTX data lookin real gooood
0 · Reply
YOLODiamondHand
YOLODiamondHand Sep. 13 at 3:25 AM
$BNTX trending 😅
0 · Reply
1dayatadime
1dayatadime Sep. 13 at 1:24 AM
$BNTX holy shit
0 · Reply
fredbull
fredbull Sep. 13 at 12:56 AM
$BNTX 300+ Monday
1 · Reply
htw7448
htw7448 Sep. 13 at 12:53 AM
$BNTX i m pretty shure they will get accelerated approval for that. At least for second and third line. For first line of course some more work to do, but with these data they will also get standard of care.
0 · Reply
Latest News on BNTX
BioNTech price target lowered to $136 from $142 at Canaccord

2026-08-31T11:05:30.000Z - 13 days ago

BioNTech price target lowered to $136 from $142 at Canaccord


BioNTech to terminate mid-stage trial of mRNA cancer vaccine

Aug 28, 2026, 9:41 AM EDT - 16 days ago

BioNTech to terminate mid-stage trial of mRNA cancer vaccine


BioNTech to terminate Phase 2 monotherapy trial of cevumeran

2026-08-28T13:10:11.000Z - 16 days ago

BioNTech to terminate Phase 2 monotherapy trial of cevumeran


BioNTech rises 20.3%

2026-08-19T16:05:37.000Z - 25 days ago

BioNTech rises 20.3%


BioNTech rises 21.6%

2026-08-19T14:00:12.000Z - 25 days ago

BioNTech rises 21.6%


BioNTech price target raised to $142 from $138 at Canaccord

2026-08-05T11:05:37.000Z - 5 weeks ago

BioNTech price target raised to $142 from $138 at Canaccord


BioNTech price target lowered to $125 from $130 at Citi

2026-08-05T10:35:32.000Z - 5 weeks ago

BioNTech price target lowered to $125 from $130 at Citi


BioNTech SE Earnings Call Transcript: Q2 2026

Aug 4, 2026, 8:00 AM EDT - 5 weeks ago

BioNTech SE Earnings Call Transcript: Q2 2026


BioNTech SE Earnings release: Q2 2026

Aug 4, 2026, 8:00 AM EDT - 5 weeks ago

BioNTech SE Earnings release: Q2 2026


BioNTech SE Slides: Q2 2026

Aug 4, 2026, 8:00 AM EDT - 5 weeks ago

BioNTech SE Slides: Q2 2026


BioNTech says Sobi's Oelkers will replace Sahin as CEO

Aug 3, 2026, 5:29 AM EDT - 5 weeks ago

BioNTech says Sobi's Oelkers will replace Sahin as CEO


This Biotech's Cancer Portfolio Could End Its Rough Patch

May 27, 2026, 11:07 AM EDT - 3 months ago

This Biotech's Cancer Portfolio Could End Its Rough Patch


BioNTech SE Transcript: AGM 2026

May 15, 2026, 8:00 AM EDT - 4 months ago

BioNTech SE Transcript: AGM 2026


BioNTech Announces New ADS Repurchase Program

May 7, 2026, 6:45 AM EDT - 4 months ago

BioNTech Announces New ADS Repurchase Program


BioNTech SE Earnings Call Transcript: Q1 2026

May 5, 2026, 8:00 AM EDT - 4 months ago

BioNTech SE Earnings Call Transcript: Q1 2026


BioNTech SE Earnings release: Q1 2026

May 5, 2026, 8:00 AM EDT - 4 months ago

BioNTech SE Earnings release: Q1 2026


BioNTech SE Slides: Q1 2026

May 5, 2026, 8:00 AM EDT - 4 months ago

BioNTech SE Slides: Q1 2026


BioNTech SE Earnings Call Transcript: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 6 months ago

BioNTech SE Earnings Call Transcript: Q4 2025


BioNTech SE Annual report: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 6 months ago

BioNTech SE Annual report: Q4 2025


BioNTech SE Earnings release: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 6 months ago

BioNTech SE Earnings release: Q4 2025


BioNTech SE Slides: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 6 months ago

BioNTech SE Slides: Q4 2025


Scientists behind COVID-19 vaccine will depart BioNTech

Mar 10, 2026, 7:40 AM EDT - 6 months ago

Scientists behind COVID-19 vaccine will depart BioNTech


BioNTech Cofounders to Leave to Form New Company

Mar 10, 2026, 6:50 AM EDT - 6 months ago

BioNTech Cofounders to Leave to Form New Company


BioNTech says collaboration with Pfizer remains unchanged

Nov 13, 2025, 8:17 AM EST - 10 months ago

BioNTech says collaboration with Pfizer remains unchanged

PFE


BioNTech SE Transcript: R&D Day

Nov 11, 2025, 9:00 AM EST - 10 months ago

BioNTech SE Transcript: R&D Day


BioNTech SE Slides: R&D Day

Nov 11, 2025, 9:00 AM EST - 10 months ago

BioNTech SE Slides: R&D Day


BioNTech SE Earnings Call Transcript: Q3 2025

Nov 3, 2025, 8:00 AM EST - 10 months ago

BioNTech SE Earnings Call Transcript: Q3 2025


BioNTech SE Earnings release: Q3 2025

Nov 3, 2025, 8:00 AM EST - 10 months ago

BioNTech SE Earnings release: Q3 2025


BioNTech SE Slides: Q3 2025

Nov 3, 2025, 8:00 AM EST - 10 months ago

BioNTech SE Slides: Q3 2025


BioNTech lifts 2025 revenue guidance on BMS partnership payment

Nov 3, 2025, 6:47 AM EST - 10 months ago

BioNTech lifts 2025 revenue guidance on BMS partnership payment


AIIAAIIA_88
AIIAAIIA_88 Sep. 13 at 5:02 PM
$BNTX MRNA's success against melanoma is like a child's play when compared to BNTX's success against small call lung cancer. The mRNA method has been used successfully against skin cancer for some time. The medical field knows about it. But SCLC is very tough. BNTX's P 1/2b data are not just great. It is wildly beyond what has been expected for SCLC. It is groundbreaking. Anyone who wants to downplay is either intentionally lying or extremely ignorant. JMO
0 · Reply
fredbull
fredbull Sep. 13 at 4:22 PM
$BNTX triple from here
0 · Reply
wintogether
wintogether Sep. 13 at 2:57 PM
$BNTX obviously happy for my small holdings here, but really hopeful for the patients and the field. These guys are proving to be the best in class.
0 · Reply
cubie
cubie Sep. 13 at 1:35 PM
$BNTX $MRNA @YOLODiamondHand congrats giddy bulls
1 · Reply
eightytwentie
eightytwentie Sep. 13 at 3:34 AM
$BNTX PD-L1 x VEGF-A bispecific antibody plus B7H3 antibody-drug conjugate show 70.4% ORR
0 · Reply
eightytwentie
eightytwentie Sep. 13 at 3:32 AM
$BNTX data lookin real gooood
0 · Reply
YOLODiamondHand
YOLODiamondHand Sep. 13 at 3:25 AM
$BNTX trending 😅
0 · Reply
1dayatadime
1dayatadime Sep. 13 at 1:24 AM
$BNTX holy shit
0 · Reply
fredbull
fredbull Sep. 13 at 12:56 AM
$BNTX 300+ Monday
1 · Reply
htw7448
htw7448 Sep. 13 at 12:53 AM
$BNTX i m pretty shure they will get accelerated approval for that. At least for second and third line. For first line of course some more work to do, but with these data they will also get standard of care.
0 · Reply
htw7448
htw7448 Sep. 13 at 12:49 AM
$BNTX i would sell my ass if this does nt pop above 130$ on monday.
1 · Reply
htw7448
htw7448 Sep. 13 at 12:47 AM
$BNTX nice safety profil too → 0 DLTs → Grade ≥3 TRAEs only 23.3 % → no ILD‑signals → no VEGF‑catastrophs → no ADC‑typic showstopper this is far better than most of available ADCs.
1 · Reply
htw7448
htw7448 Sep. 13 at 12:43 AM
$BNTX this data set is far above everything available today, its a MASSIVE SHIFT for SCLC for newbies, available therapies are: Topotecan: ORR 10–20 % Lurbinectedin: ORR 35 % DLL3‑ADCs: ORR 40–50 %, kinda toxic IO‑Rechallenge: ORR 5–15 % BNTX delivered with PUMI + ELFE: 👉 70 % ORR 👉 92 % ORR in First‑Line 👉 77 % ORR in Second‑Line 👉 52 % ORR in Third‑Line+ 👉 70 % ORR after DLL3‑Therapie !!! This will trigger a massive reevaluation of $BNTX !!! Their pipeline works, and they are unbeatable!
1 · Reply
Money_mitch_
Money_mitch_ Sep. 13 at 12:19 AM
$BNTX https://www.iaslc.org/iaslc-news/press-release/pumitamig-plus-elfetabart-drozuntecan-shows-encouraging-early-activity
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Sep. 12 at 11:38 PM
$BNTX The lung cancer world conference in Seoul, Korea is on 9/12 - 9/15. Since Seoul is one day ahead of the USA, we will hear all the news by the end of Monday, 9/14. The global lung cancer market is about $31B. BNTX will be in mid to high triple digits, when its pipelines for lung cancer work out. JMO
0 · Reply
Samishere
Samishere Sep. 12 at 2:32 AM
0 · Reply
cubie
cubie Sep. 11 at 11:07 PM
$BNTX ✔️ $VG ✔️ $ORCL all day ✔️ $QQQ ✔️ $AAPL 🤭😅
0 · Reply
YOLODiamondHand
YOLODiamondHand Sep. 11 at 9:32 PM
$BNTX @cubie what ya think about this stock? Supposedly they gonna have their data on lung cancer drug over the weekend
3 · Reply
Lambo2
Lambo2 Sep. 11 at 8:35 PM
0 · Reply
htw7448
htw7448 Sep. 11 at 7:21 PM
$BNTX Pumitamig + Elfetabart Drozuntecan ftw
0 · Reply
1dayatadime
1dayatadime Sep. 11 at 7:03 PM
$BNTX $MRNA IMHO if BNTX shows in the data that its potential is similar to MRNA research we can double here due to what’s coming in the pipeline and like you said the cash to execute
1 · Reply
Samishere
Samishere Sep. 11 at 6:08 PM
0 · Reply